Molecular biosignatures that identify an inflammatory and potentially adverse reaction to vaccination have been defined in mice, a critical gatekeeper for progression of novel vaccine candidates into humans.

In a study of a herpes simplex virus (HSV) vaccine, the combination of sex and prior exposure to the virus resulted in HSV naive women mounting a prominent type I interferon response associated with reduced neutralizing titers to HSV.

COVID-19 mRNA vaccine-elicited T cells recognize variants of concern and phenotypically differ depending on number of vaccine doses and prior SARS-CoV-2 infection status.

Analysis of protein content and protein composition of the ChAdOx1 nCov-19 vaccine, but not of the Ad26.COV2.S vaccine, indicated significantly higher than expected levels of host cell proteins (HCPs) and of free viral proteins.

A review of the current empirical literature underscores the need for longitudinal research examining potential spillover effects between hesitancy, intention, or uptake for the COVID vaccine and HPV and HBV vaccines, especially to account for social media misinformation.

Small changes to the way COVID-19 vaccine side-effect rates are framed and communicated have meaningful impacts on individuals' vaccination intentions.

Providing important data regarding the proportion of COVID-19 vaccine hesitancy and barriers toward vaccination in Arabic-speaking people to guide addressing the problem and achievement of widespread vaccination and collective immunity.

Using single-cell CITE-seq to implicate monocytes as the cellular origin of a protective HIV vaccine gene signature.

Third dose of COVID-19 vaccine leads to seroconversion in 56% cancer patients that are seronegative after primary vaccination and a fourth can further boost immune response in patients with hematologic malignancies, which can be predicted by IgM and CD19 levels.

An immunopeptidomic-based pipeline provides a tool for the identification of cancer therapeutic targets and generation of cancer oncolytic vaccines.